Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Dong, Li Hua ^a   Cheng, Shu ^a   Zheng, Zhong ^a   Wang, Li ^a,b   Shen, Yang ^a   Shen, Zhi Xiang ^a   Chen, Sai Juan ^a,b   Zhao, Wei Li ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Laboratory of Molecular Pathology   (China)

Author keywords

Autophagy; Burkitt leukemia lymphoma; Histone deacetylase inhibitor; MTOR inhibitor; MYC

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HISTONE DEACETYLASE 1; SMALL INTERFERING RNA; TEMSIROLIMUS; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; BURKITT LYMPHOMA; CELL DEATH; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE SILENCING; HEMATOPOIESIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIMARY TUMOR; TUMOR CELL; TUMOR REGRESSION; TUMOR XENOGRAFT;

EID: 84880184328     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-53     Document Type: Article

References (34)

1. Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis. Sander S, Calado DP, Srinivasan L, Kochert K, Zhang B, Rosolowski M, Rodig SJ, Holzmann K, Stilgenbauer S, Siebert R, et al. Cancer Cell 2012 22 2 167 179 10.1016/j.ccr.2012.06.012 22897848
2. Adult Burkitt leukemia and lymphoma. Blum KA, Lozanski G, Byrd JC, Blood 2004 104 10 3009 3020 10.1182/blood-2004-02-0405 15265787 (Pubitemid 39507113)
3. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B, Autophagy 2010 6 3 322 329 10.4161/auto.6.3.11625 20224296
4. Autophagy fights disease through cellular self-digestion. Mizushima N, Levine B, Cuervo AM, Klionsky DJ, Nature 2008 451 7182 1069 1075 10.1038/nature06639 18305538 (Pubitemid 351317450)
5. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, et al. J Clin Invest 2003 112 12 1809 1820 14638851 (Pubitemid 38063704)
6. Beclin 1 expression predicts favorable clinical outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Huang JJ, Zhu YJ, Lin TY, Jiang WQ, Huang HQ, Li ZM, Hum Pathol 2011 42 10 1459 1466 10.1016/j.humpath. 2010.12.014 21450329
7. Beclin 1 expression: a predictor of prognosis in patients with extranodal natural killer T-cell lymphoma, nasal type. Huang JJ, Li HR, Huang Y, Jiang WQ, Xu RH, Huang HQ, Lv Y, Xia ZJ, Zhu XF, Lin TY, et al. Autophagy 2010 6 6 777 783 10.4161/auto.6.6.12784 20639699
8. Targeted therapy in lymphoma. Johnston PB, Yuan R, Cavalli F, Witzig TE, J Hematol Oncol 2010 3 45 10.1186/1756-8722-3-45 21092307
9. mTOR: from growth signal integration to cancer, diabetes and ageing. Zoncu R, Efeyan A, Sabatini DM, Nat Rev Mol Cell Biol 2011 12 1 21 35 10.1038/nrm3025 21157483
10. Signal transduction inhibitor therapy for lymphoma. Witzig TE, Gupta M, Hematology Am Soc Hematol Educ Program 2010 2010 265 270 10.1182/asheducation- 2010.1.265 21239804
11. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. Yuan R, Kay A, Berg WJ, Lebwohl D, J Hematol Oncol 2009 2 45 10.1186/1756-8722-2-45 19860903
12. Histone deacetylases and cancer: causes and therapies. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK, Nat Rev Cancer 2001 1 3 194 202 10.1038/35106079 11902574 (Pubitemid 33741894)
13. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. Cang S, Ma Y, Liu D, J Hematol Oncol 2009 2 22 10.1186/1756-8722-2-22 19486511
14. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP, Exp Hematol 2005 33 1 53 61 10.1016/j.exphem.2004.09.008 15661398 (Pubitemid 40127644)
15. Valproic acid monotherapy leads to CR in a patient with refractory diffuse large B cell lymphoma. Zain J, Rotter A, Weiss L, Forman S, Kirschbaum MH, Leuk Lymphoma 2007 48 6 1216 1218 10.1080/10428190701344907 17577787 (Pubitemid 47009213)
16. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, Stenmark H, Johansen T, J Cell Biol 2005 171 4 603 614 10.1083/jcb.200507002 16286508 (Pubitemid 41668720)
17. Hallmarks of cancer: the next generation. Hanahan D, Weinberg RA, Cell 2011 144 5 646 674 10.1016/j.cell.2011.02.013 21376230
18. Novel therapeutic agents for B-cell lymphoma: developing rational combinations. Reeder CB, Ansell SM, Blood 2011 117 5 1453 1462 10.1182/blood-2010-06-255067 20978267
19. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. Catalano MG, Fortunati N, Pugliese M, Costantino L, Poli R, Bosco O, Boccuzzi G, J Clin Endocrinol Metab 2005 90 3 1383 1389 15585556 (Pubitemid 40463993)
20. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A, Armand JP, J Clin Oncol 2004 22 12 2336 2347 10.1200/JCO.2004.08.116 15136596 (Pubitemid 41115390)
21. Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors. Coulter DW, Walko C, Patel J, Moats-Staats BM, McFadden A, Smith SV, Khan WA, Bridges AS, Deal AM, Oesterheld J, Davis IJ, Blatt J, Anticancer Drugs 2013 24 4 415 421 10.1097/CAD.0b013e32835dc7c5 23328074
22. The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt's lymphoma. Cloonan SM, Williams DC, Int J Cancer 2011 128 7 1712 1723 10.1002/ijc.25477 20503272
23. Involvement of macroautophagy in the caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Turzanski J, Daniels I, Haynes AP, Br J Haematol 2009 145 1 137 140 10.1111/j.1365-2141.2008.07555.x 19183195
24. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Yazbeck VY, Buglio D, Georgakis GV, Li Y, Iwado E, Romaguera JE, Kondo S, Younes A, Exp Hematol 2008 36 4 443 450 10.1016/j.exphem.2007.12.008 18343280 (Pubitemid 351384743)
25. Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Fu J, Shao CJ, Chen FR, Ng HK, Chen ZP, Neuro Oncol 2010 12 4 328 340 10.1093/neuonc/nop005 20308311
26. Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells. Francisco R, Perez-Perarnau A, Cortes C, Gil J, Tauler A, Ambrosio S, Cancer Lett 2012 318 1 42 52 10.1016/j.canlet.2011.11.036 22186300
27. HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer. Xie HJ, Noh JH, Kim JK, Jung KH, Eun JW, Bae HJ, Kim MG, Chang YG, Lee JY, Park H, et al. PLoS One 2012 7 4 34265 10.1371/journal.pone.0034265 22496786
28. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE, Blood 2009 114 14 2926 2935 10.1182/blood-2009-05-220889 19641186
29. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Liu YL, Yang PM, Shun CT, Wu MS, Weng JR, Chen CC, Autophagy 2010 6 8 1057 1065 10.4161/auto.6.8.13365 20962572
30. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Memmott RM, Dennis PA, Cell Signal 2009 21 5 656 664 10.1016/j.cellsig.2009.01. 004 19166931
31. Myc proteins as therapeutic targets. Gustafson WC, Weiss WA, Oncogene 2010 29 9 1249 1259 10.1038/onc.2009.512 20101214
32. MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Balakumaran BS, Porrello A, Hsu DS, Glover W, Foye A, Leung JY, Sullivan BA, Hahn WC, Loda M, Febbo PG, Cancer Res 2009 69 19 7803 7810 10.1158/0008-5472.CAN-09-0910 19773438
33. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. Kluk MJ, Chapuy B, Sinha P, Roy A, Dal Cin P, Neuberg DS, Monti S, Pinkus GS, Shipp MA, Rodig SJ, PLoS One 2012 7 4 33813 10.1371/journal.pone. 0033813 22511926
34. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ, et al. Leukemia 2009 23 8 1507 1514 10.1038/leu.2009.41 19282831